الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Distinguishing vitiligo stability from activity appears to be crucial, especially for control of early progressive vitiligo as well as for surgical treatment. Although diagnosis of vitiligo is primarily clinical, certain non- invasive tests like dermoscopy are helpful especially in doubtful cases (in evolving disease), and for objective evaluation of treatment response. Furthermore, certain substances released in tissues and sera of vitiligo patients can assist in detection of vitiligo status such as; CXCL-10, a chemokine released in response to IFN-Þ, that represents an indicator of disease activity. Some studies identified a critical role for CXCL10 in both the progression and maintenance of vitiligo and thereby supported inhibiting CXCL10 as a targeted treatment strategy. Aim of work: We aim to detect the dermoscopic findings in active and stable vitiligo, and to correlate these findings with VIDA scores, clinical signs of activity and stability as well as CXCL10 serum levels. Patients and Methods: The study was conducted between March 2019 and March 2020. 97 clinically diagnosed vitiligo patients were enrolled and assessed using VIDA scores and clinical examination to detect signs of activity and stability in vitiligo. Further evaluation using dermoscopy was performed and dermoscopic scores were calculated by the use of the modified BPLeFoSK score. A blood sample was taken from each patient to measure serum CXCL10 by ELISA technique. Results: According to VIDA scores, 51.5% of the patients had active vitiligo while 48.5% had stable vitiligo. Clinically, 63.9% of the patients had active vitiligo while 36.1% had stable vitiligo |